Skip to main content

Agenus to Participate in Oppenheimer 34th Annual Healthcare Life Sciences Conference

 

Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that Dr. Garo Armen, Chairman and CEO, will participate in a fireside chat and investor one-on-ones at the upcoming Oppenheimer Healthcare Conference on February 13th - 14th. The fireside chat will take place at 8:00 a.m. ET on February 14th.

A live webcast and replay of the fireside chat will be accessible on the company’s website at https://investor.agenusbio.com/events-and-presentations.

About Agenus

Agenus is a leading immuno-oncology company targeting cancer and infectious diseases with a comprehensive pipeline of immunological agents. The company’s mission is to expand patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants (through SaponiQx). Agenus is headquartered in Lexington, MA. For more information, visit www.agenusbio.com or @agenus_bio. Information that may be important to investors will be routinely posted on our website and social media channels.

Contacts

Recent Quotes

View More
Symbol Price Change (%)
AMZN  232.14
+3.71 (1.62%)
AAPL  272.36
+1.39 (0.51%)
AMD  214.90
-0.05 (-0.02%)
BAC  55.97
+0.09 (0.16%)
GOOG  315.68
+4.35 (1.40%)
META  664.94
+3.44 (0.52%)
MSFT  486.85
+1.93 (0.40%)
NVDA  189.21
+5.52 (3.01%)
ORCL  195.34
-3.04 (-1.53%)
TSLA  485.56
-3.17 (-0.65%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.